肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 ESMO临床实践指南：新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访

2020-11-23 欧洲肿瘤内科学会 Ann Oncol . 2020 Nov 23;

复发性滤泡性淋巴瘤

2020年11月，欧洲肿瘤内科学会(ESMO)发布了新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访指南，指南主要内容包括滤泡性淋巴瘤的诊断以及病理/分子诊断，分期和危险分层，局部滤泡性淋巴瘤的治疗，晚期

中文标题：

2020 ESMO临床实践指南：新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访

英文标题：

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

发布机构：

欧洲肿瘤内科学会

发布日期：

2020-11-23

简要介绍：

2020年11月，欧洲肿瘤内科学会(ESMO)发布了新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访指南，指南主要内容包括滤泡性淋巴瘤的诊断以及病理/分子诊断，分期和危险分层，局部滤泡性淋巴瘤的治疗，晚期滤泡淋巴瘤的治疗，个体化医疗，随访等。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南：新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=4153d1c0020258ef, title=2020 ESMO临床实践指南：新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访, enTitle=Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, guiderFrom=Ann Oncol . 2020 Nov 23;, authorId=0, author=, summary=2020年11月，欧洲肿瘤内科学会(ESMO)发布了新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访指南，指南主要内容包括滤泡性淋巴瘤的诊断以及病理/分子诊断，分期和危险分层，局部滤泡性淋巴瘤的治疗，晚期, cover=https://img.medsci.cn/20201219/1608389870117_2020535.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Mon Nov 23 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年11月，欧洲肿瘤内科学会(ESMO)发布了新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访指南，指南主要内容包括滤泡性淋巴瘤的诊断以及病理/分子诊断，分期和危险分层，局部滤泡性淋巴瘤的治疗，晚期滤泡淋巴瘤的治疗，个体化医疗，随访等。</p> </div> </div> </div>, tagList=[TagDto(tagId=58919, tagName=复发性滤泡性淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=10568, guiderKeyword=滤泡性淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10397, appHits=238, showAppHits=0, pcHits=577, showPcHits=10159, likes=8, shares=44, comments=29, approvalStatus=1, publishedTime=Sun Dec 20 00:15:40 CST 2020, publishedTimeString=2020-11-23, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Dec 19 22:57:58 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Wed Jan 03 11:52:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南：新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访.pdf)])
2020 ESMO临床实践指南：新诊断及复发性滤泡性淋巴瘤的诊断，治疗和随访.pdf
下载请点击：
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1248012, encodeId=d9c812480124d, content=好，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d222471257, createdName=1243a20em71(暂无昵称), createdTime=Fri Sep 09 01:12:10 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056546, encodeId=fe5a10565469d, content=与时俱进。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:44 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052442, encodeId=b587105244251, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=de265461846, createdName=ms8000002032308054, createdTime=Fri Sep 17 22:35:21 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007034, encodeId=148a100e034aa, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c985570737, createdName=ms4000001344423915, createdTime=Wed Aug 11 20:18:43 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005531, encodeId=6b07100553180, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=咸鱼真楠, createdTime=Fri Aug 06 07:54:11 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2022-09-09 1243a20em71(暂无昵称)

    好，学习了。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1248012, encodeId=d9c812480124d, content=好，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d222471257, createdName=1243a20em71(暂无昵称), createdTime=Fri Sep 09 01:12:10 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056546, encodeId=fe5a10565469d, content=与时俱进。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:44 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052442, encodeId=b587105244251, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=de265461846, createdName=ms8000002032308054, createdTime=Fri Sep 17 22:35:21 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007034, encodeId=148a100e034aa, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c985570737, createdName=ms4000001344423915, createdTime=Wed Aug 11 20:18:43 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005531, encodeId=6b07100553180, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=咸鱼真楠, createdTime=Fri Aug 06 07:54:11 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-09-30 13f0c37dm61暂无昵称

    与时俱进。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1248012, encodeId=d9c812480124d, content=好，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d222471257, createdName=1243a20em71(暂无昵称), createdTime=Fri Sep 09 01:12:10 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056546, encodeId=fe5a10565469d, content=与时俱进。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:44 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052442, encodeId=b587105244251, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=de265461846, createdName=ms8000002032308054, createdTime=Fri Sep 17 22:35:21 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007034, encodeId=148a100e034aa, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c985570737, createdName=ms4000001344423915, createdTime=Wed Aug 11 20:18:43 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005531, encodeId=6b07100553180, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=咸鱼真楠, createdTime=Fri Aug 06 07:54:11 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-09-17 ms8000002032308054

    赞

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1248012, encodeId=d9c812480124d, content=好，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d222471257, createdName=1243a20em71(暂无昵称), createdTime=Fri Sep 09 01:12:10 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056546, encodeId=fe5a10565469d, content=与时俱进。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:44 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052442, encodeId=b587105244251, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=de265461846, createdName=ms8000002032308054, createdTime=Fri Sep 17 22:35:21 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007034, encodeId=148a100e034aa, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c985570737, createdName=ms4000001344423915, createdTime=Wed Aug 11 20:18:43 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005531, encodeId=6b07100553180, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=咸鱼真楠, createdTime=Fri Aug 06 07:54:11 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-08-11 ms4000001344423915

    赞

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1248012, encodeId=d9c812480124d, content=好，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d222471257, createdName=1243a20em71(暂无昵称), createdTime=Fri Sep 09 01:12:10 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056546, encodeId=fe5a10565469d, content=与时俱进。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:32:44 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052442, encodeId=b587105244251, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=de265461846, createdName=ms8000002032308054, createdTime=Fri Sep 17 22:35:21 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007034, encodeId=148a100e034aa, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c985570737, createdName=ms4000001344423915, createdTime=Wed Aug 11 20:18:43 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005531, encodeId=6b07100553180, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=咸鱼真楠, createdTime=Fri Aug 06 07:54:11 CST 2021, time=2021-08-06, status=1, ipAttribution=)]
    2021-08-06 咸鱼真楠

    赞

    0

以上为热门评论，梅斯医学App还有更多内容

拓展阅读

2016 ESMO临床诊疗指南：新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

2018 多学科意见书：慢性淋巴细胞白血病和滤泡性淋巴瘤应用艾代拉利司治疗相关不良事件的管理

国外血液科相关专家小组 · 2018-09-05

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：滤泡性淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-06-06

2020 BSH指南：滤泡性淋巴瘤的调查和管理

英国血液病学学会(BSH,British Society for Haematology) · 2020-06-24

中国滤泡性淋巴瘤诊断与治疗指南（2020年版）

中国抗癌协会淋巴瘤专业委员会 · 2020-07-30

2023 NICE 技术鉴定指导意见：莫妥珠单抗用于治疗复发或难治性滤泡性淋巴瘤[TA892]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-05-31